

Stepwise Approach: 0-4 years


2020 EPR 3 Updates/GINA Hybrid



NEW YORK STATE



At every visit, check inhaler technique, medication adherence, and assess for environmental triggers.



Stepwise Approach: 0-4 years

Additional Notes



NEW YORK STATE



At every visit:

- check inhaler technique
- check medication adherence
- assess for environmental triggers



Consider consult with asthma specialist at **Steps 1 and 2**

Recommend consult with asthma specialist at **Steps 3-6**



Montelukast has an **FDA Boxed Warning** due to risk of serious adverse neuropsychiatric side effects and is no longer recommended as an asthma controller medication.



Alternative Reliever Therapy at **Steps 3 and 4** for ages greater than or equal to 4 years

Consider **SMART** (Single Maintenance and Reliever Therapy) in consultation with a specialist

ICS + Formoterol PRN

- 1-2 puffs at a time, max 8 puffs per day for maintenance + reliever

Abbreviations

EPR 3

Expert Panel Report 3

GINA

Global Initiative for Asthma

PRN

As Needed

ICS

Inhaled Corticosteroids

URI

Upper Respiratory Infection

LABA

Long-Acting Beta-Agonist

LAMA

Long-Acting Muscarinic Antagonist

OCS

Oral Corticosteroid

SABA

Short-Acting Beta-Agonist